Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W. Roloff, George Yaghmour, Ibrahim Aldoss et al.|Journal of Clinical Oncology|2024Cited by 36
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALLIbrahim Aldoss, Betsy Blunk, Gregory W. Roloff et al.|Blood Advances|2024Cited by 12
Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell TransplantationNirali N. Shah, Guenther Koehne, Jacques Azzi et al.|Blood|2023Cited by 12
Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)John F. DiPersio, Guenther Koehne, Hyung C. Suh et al.|Blood|2023Cited by 11
A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abataceptDivya Koura, Dimitrios Tzachanis, Kaitlyn C. Dykes et al.|Blood Advances|2025Cited by 7